NCT06178588 2026-02-24Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic CholangiocarcinomaUniversity of Kansas Medical CenterPhase 2 Active not recruiting15 enrolled